It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
HPV-driven oropharyngeal carcinomas (OPCs) show geographical variations with increasing temporal trends in several areas. We investigated their frequency and clinical outcomes within a prospective multicenter cohort study in North-East Italy. A tumor was defined as HPV-driven by using at least two different biomarkers, usually HPV-DNA positivity and p16INK4A overexpression. Different survival outcomes were compared among patients with HPV-driven and non-HPV-driven tumors. Overall, 42/130 (32.3%) patients with newly diagnosed OPC during the period 2000–2018 resulted HPV-driven; HPV16 was involved in 37 cases (88%), HPV33 in 3 cases (7%), HPV58 and HPV18 in 1 case each. Over time, HPV-driven cases raised from 16.7% (6/36) during 2000–2006 to 46.1% (24/52) during 2013–2018 (p < 0.001). The increase in HPV-driven OPCs was more marked in females than males (p = 0.010), and the frequency of HPV-driven cases was similar in the different age groups. In comparison to cases with non-HPV-driven tumors, a significantly (p < 0.001) better progression-free and overall survival were recorded among patients affected by HPV-driven OPC. The prevalence of HPV-driven OPC cases has been significantly increasing during the last two decades also in North-East Italy and was associated with favorable outcome. OPCs driven by non-HPV16 oncogenic types were restricted to patients older than 68-yrs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV – IRCCS, Padova, Italy (GRID:grid.419546.b) (ISNI:0000 0004 1808 1697)
2 Department of Neurosciences DNS, Section of Otolaryngology, University of Padova, Treviso, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
3 Department of Neurosciences DNS, Section of Otolaryngology, University of Padova, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
4 Department of Neurosciences DNS, Section of Otolaryngology, University of Padova, Treviso, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
5 Anatomical Pathology Unit, San Donà di Piave Hospital, Azienda ULSS 4 Veneto Orientale, San Donà di Piave, Italy (GRID:grid.5608.b)
6 Head and Neck Department, Cattinara Hospital, University of Trieste, Trieste, Italy (GRID:grid.5608.b)
7 Unit of Cancer Epidemiology, Aviano National Cancer Institute, IRCCS, Aviano, Italy (GRID:grid.414603.4)